Stocks › JAZZ
Jazz Pharmaceuticals plc
JAZZ·Nasdaq·USD
$230.26
-6.19 (-2.62%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
JAZZ
Jazz Pharmaceuticals plc · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
JAZZS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of JAZZ by members of U.S. Congress · 16 on record
Whale Activity
Position changes in JAZZ reported for 2026-09-30 by 740 institutional filers
- Increased259
- New99
- Held84
- Decreased198
- Closed66
- No prior filing34
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 6.5M | $1.49B | increased |
| FMR LLC | 5.5M | $1.28B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | $711.2M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.8M | $649.5M | increased |
| Capital World Investors | 2.4M | $554.1M | decreased |
| LSV ASSET MANAGEMENT | 2.1M | $494.5M | — |
| STATE STREET CORP | 2.1M | $478.8M | increased |
| FRANKLIN TEMPLETON INC | 1.9M | $456.2M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5M | $354.9M | increased |
| DIMENSIONAL FUND ADVISORS LP | 1.5M | $336.5M | decreased |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1.4M | $323.8M | decreased |
| AQR CAPITAL MANAGEMENT LLC | 1.2M | $271.0M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by JAZZ insiders, by quarter · Form 4
Recent Insider Transactions
2,061 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| COZADD BRUCE CDirector · Director | Sale | −5,923 | $237.39 | $1.4M | Nov 6, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −27.7K | $234.91 | $6.5M | Nov 6, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −24.5K | $236.84 | $5.8M | Nov 6, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −10.7K | $235.82 | $2.5M | Nov 6, 2026 | Form 4 ↗ |
| Carr PatriciaSVP, Chief Accounting Officer | Sale | −163 | $231.27 | $38K | Nov 4, 2026 | Form 4 ↗ |
| Carr PatriciaSVP, Chief Accounting Officer | Sale | −1,250 | $231.37 | $289K | Nov 4, 2026 | Form 4 ↗ |
| GALA RENEE DPresident & CEO · Director | Sale | −1,000 | $225.37 | $225K | Nov 3, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −6,000 | $215.84 | $1.3M | Nov 2, 2026 | Form 4 ↗ |
| GALA RENEE DPresident & CEO · Director | Sale | −2,000 | $236.40 | $473K | Oct 6, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector · Director | Sale | −6,000 | $230.33 | $1.4M | Oct 1, 2026 | Form 4 ↗ |
| Patil Neena MEVP & Chief Legal Officer | Sale | −1,200 | $240.94 | $289K | Sep 10, 2026 | Form 4 ↗ |
| Henderson Mary ElizabethSVP, Technical Operations | Tax withholding | −15 | $241.20 | $4K | Sep 8, 2026 | Form 4 ↗ |
| Henderson Mary ElizabethSVP, Technical Operations | Tax withholding | −1,412 | $243.03 | $343K | Sep 8, 2026 | Form 4 ↗ |
| GALA RENEE DPresident & CEO | Sale | −2,000 | $243.03 | $486K | Sep 8, 2026 | Form 4 ↗ |
| GALA RENEE DPresident & CEO | Tax withholding | −1,967 | $246.81 | $485K | Sep 8, 2026 | Form 4 ↗ |
| COZADD BRUCE CDirector | Sale | −6,000 | $250.13 | $1.5M | Sep 1, 2026 | Form 4 ↗ |
| Kennedy PatrickDirector | Tax withholding | −1,840 | $241.39 | $444K | Aug 31, 2026 | Form 4 ↗ |
| Kennedy PatrickDirector | Tax withholding | −15 | $244.06 | $4K | Aug 31, 2026 | Form 4 ↗ |
| Henderson Mary ElizabethSVP, Technical Operations | Tax withholding | −16 | $244.64 | $4K | Aug 31, 2026 | Form 4 ↗ |
| Henderson Mary ElizabethSVP, Technical Operations | Tax withholding | −2,076 | $241.39 | $501K | Aug 31, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding JAZZ · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $456.0M | 0.02% | Jun 30, 2026 |
| FULLERTHALER BEHAVIORAL SMALL CAP EQUITY Capitol Series Trust | 1.6M | $376.3M | 2.97% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $329.3M | 0.17% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 865.9K | $208.7M | 0.31% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 719.2K | $173.3M | 0.18% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF Victory Portfolios II | 469.9K | $113.2M | 1.46% | Jun 30, 2026 |
| Avantis U.S. Large Cap Value ETF American Century ETF Trust | 221.3K | $55.5M | 0.26% | Aug 31, 2026 |
| Dimensional U.S. Small Cap ETF Dimensional ETF Trust | 168.6K | $42.6M | 0.28% | Jul 31, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 169.1K | $42.4M | 0.19% | Aug 31, 2026 |
| VANGUARD WINDSOR FUND VANGUARD WINDSOR FUNDS | 201.6K | $40.9M | 0.17% | Apr 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list JAZZ's shares (CUSIP G50871105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming jazz pharmaceuticals as client
- MARSHALL & POPP, LLCJAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES · 2026 Q3 · HCR, TRD$40K
Filing ↗ - AVENUE SOLUTIONSJAZZ PHARMACEUTICALS, INC. · 2026 Q3 · HCR, MMM$50K
Filing ↗ - JAZZ PHARMACEUTICALS, INC.JAZZ PHARMACEUTICALS, INC. · 2026 Q3 · PHA$550K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCJAZZ PHARMACEUTICALS INC. · 2026 Q3 · HCR$80K
Filing ↗ - THE NICKLES GROUP, LLCJAZZ PHARMACEUTICALS, INC. · 2026 Q3 · MMM, TRD$50K
Filing ↗
Government Contracts
Federal awards to jazz pharmaceuticals · USAspending
$517KAwarded · 3 contracts on record
U.S. Patents
Recent USPTO applications naming Jazz Pharmaceuticals plc
No USPTO patent applications found for Jazz Pharmaceuticals plc.
Annual Financials
From JAZZ's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M |
| Diluted EPS | -$5.84 | $8.65 | $6.10 | -$3.58 | -$5.52 |
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.5M |
| Cash and equivalents | $1.39B | $2.41B | $1.51B | $881.5M | $591.4M |
| Total assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B |
| Shareholders' equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B |
As Jazz Pharmaceuticals plc tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in JAZZ's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
EDGAR ↗ - 8-K · Items 2.02Results of operationsOct 26, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeOct 9, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationSep 23, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureSep 15, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 3.02, 8.01, 9.01Material agreement · Direct financial obligation · Unregistered sale of equityAug 31, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsAug 25, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementAug 10, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 10, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
EDGAR ↗
About Jazz Pharmaceuticals plc
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersDUBLIN
IncorporatedL2
SEC CIK0001232524 ↗
Former namesJAZZ PHARMACEUTICALS INC









